Cargando…

A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure

AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kun, Wang, Le, Cong, Hongliang, Zhang, Jingxia, Hu, Yuecheng, Zhang, Yingyi, Zhang, Rui, Li, Wenyu, Qi, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065860/
https://www.ncbi.nlm.nih.gov/pubmed/35194977
http://dx.doi.org/10.1002/ehf2.13852
_version_ 1784699681705558016
author Wang, Kun
Wang, Le
Cong, Hongliang
Zhang, Jingxia
Hu, Yuecheng
Zhang, Yingyi
Zhang, Rui
Li, Wenyu
Qi, Wei
author_facet Wang, Kun
Wang, Le
Cong, Hongliang
Zhang, Jingxia
Hu, Yuecheng
Zhang, Yingyi
Zhang, Rui
Li, Wenyu
Qi, Wei
author_sort Wang, Kun
collection PubMed
description AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary artery bypass grafting (CABG) with implantation of drug‐eluting stents (DESs) in patients with mild to moderate ischaemic heart failure (EF 35–50%). It is therefore unknown whether percutaneous coronary intervention (PCI) with DES implantation can provide comparable outcomes to CABG in these patients. METHODS AND RESULTS: From January 2016 to December 2017, we enrolled patients with mildly to moderately reduced EF (35–50%) who had undergone PCI with DESs or CABG. Patients with a history of CABG, presented with acute ST‐elevation myocardial infarction (MI) or acute heart failure, and patients who had undergone CABG concomitant valvular or aortic surgery were excluded. Propensity score‐matching analysis was performed between the two groups. Kaplan–Meier analysis and multivariate Cox proportional hazard regression were applied to assess all‐cause mortality and individual end points. A total of 2050 patients (1330 PCIs and 720 CABGs) were included, and median follow‐up was 45 months (interquartile range 40 to 54). There were significant differences in all‐cause death between the two groups: 77 patients in the PCI group and 27 in the CABG group (DES vs. CABG: 5.8% vs. 3.8%, P = 0.045). After propensity score matching for the entire population, 601 matched pairs were obtained. The long‐term cumulative rate of all‐cause death was significantly different between the two groups (DES vs. CABG: 5.8% vs. 2.7%, P = 0.006). No differences were found in the rates of cardiac death (DES vs. CABG: 4.8% vs. 3.0%, P = 0.096), recurrent MI (DES vs. CABG: 4.0% vs. 2.8%, P = 0.234), and stroke (DES vs. CABG: 6.8% vs. 5.2%, P = 0.163). The rate of repeat coronary revascularization was significantly higher in the PCI group than in the CABG group (12.1% vs. 6.0%, P = 0.000). CONCLUSIONS: Considering the higher long‐term survival rate and lower repeat‐revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35–50%) and significant CAD.
format Online
Article
Text
id pubmed-9065860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90658602022-05-04 A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure Wang, Kun Wang, Le Cong, Hongliang Zhang, Jingxia Hu, Yuecheng Zhang, Yingyi Zhang, Rui Li, Wenyu Qi, Wei ESC Heart Fail Original Articles AIMS: The best revascularization strategy for patients with ischaemic heart failure (IHF) remains unclear. Current evidence and guidelines mainly focus on patients with severe ischaemic heart failure (ejection fraction [EF] < 35%). There are limited data comparing clinical outcomes of coronary artery bypass grafting (CABG) with implantation of drug‐eluting stents (DESs) in patients with mild to moderate ischaemic heart failure (EF 35–50%). It is therefore unknown whether percutaneous coronary intervention (PCI) with DES implantation can provide comparable outcomes to CABG in these patients. METHODS AND RESULTS: From January 2016 to December 2017, we enrolled patients with mildly to moderately reduced EF (35–50%) who had undergone PCI with DESs or CABG. Patients with a history of CABG, presented with acute ST‐elevation myocardial infarction (MI) or acute heart failure, and patients who had undergone CABG concomitant valvular or aortic surgery were excluded. Propensity score‐matching analysis was performed between the two groups. Kaplan–Meier analysis and multivariate Cox proportional hazard regression were applied to assess all‐cause mortality and individual end points. A total of 2050 patients (1330 PCIs and 720 CABGs) were included, and median follow‐up was 45 months (interquartile range 40 to 54). There were significant differences in all‐cause death between the two groups: 77 patients in the PCI group and 27 in the CABG group (DES vs. CABG: 5.8% vs. 3.8%, P = 0.045). After propensity score matching for the entire population, 601 matched pairs were obtained. The long‐term cumulative rate of all‐cause death was significantly different between the two groups (DES vs. CABG: 5.8% vs. 2.7%, P = 0.006). No differences were found in the rates of cardiac death (DES vs. CABG: 4.8% vs. 3.0%, P = 0.096), recurrent MI (DES vs. CABG: 4.0% vs. 2.8%, P = 0.234), and stroke (DES vs. CABG: 6.8% vs. 5.2%, P = 0.163). The rate of repeat coronary revascularization was significantly higher in the PCI group than in the CABG group (12.1% vs. 6.0%, P = 0.000). CONCLUSIONS: Considering the higher long‐term survival rate and lower repeat‐revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35–50%) and significant CAD. John Wiley and Sons Inc. 2022-02-22 /pmc/articles/PMC9065860/ /pubmed/35194977 http://dx.doi.org/10.1002/ehf2.13852 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wang, Kun
Wang, Le
Cong, Hongliang
Zhang, Jingxia
Hu, Yuecheng
Zhang, Yingyi
Zhang, Rui
Li, Wenyu
Qi, Wei
A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title_full A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title_fullStr A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title_full_unstemmed A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title_short A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
title_sort comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065860/
https://www.ncbi.nlm.nih.gov/pubmed/35194977
http://dx.doi.org/10.1002/ehf2.13852
work_keys_str_mv AT wangkun acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT wangle acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT conghongliang acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangjingxia acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT huyuecheng acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangyingyi acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangrui acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT liwenyu acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT qiwei acomparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT wangkun comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT wangle comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT conghongliang comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangjingxia comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT huyuecheng comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangyingyi comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT zhangrui comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT liwenyu comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure
AT qiwei comparisonofdrugelutingstentandcoronaryarterybypassgraftinginmildlytomoderatelyischemicheartfailure